Triple Threat: The Importance of Diagnosing "Triple-Negative" Primary Biliary Cholangitis

Dig Dis Sci. 2025 Jun 24. doi: 10.1007/s10620-025-09134-4. Online ahead of print.

Authors

Cyril Mazhuvanchery¹, Shreeya Indulkar², George Triadafilopoulos³, Hao Chi Zhang³

Affiliations

¹ Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. CBMazhuvanchery@mdanderson.org.
² Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 40555922
DOI: 10.1007/s10620-025-09134-4

No abstract available

Keywords: Anti-mitochondrial antibody; PBC Mayo Risk Score; Primary biliary cholangitis; Seronegative; Sjögren’s syndrome; Ursodeoxycholic acid.